Enjoy complimentary customisation on priority with our Enterprise License!
The neurological biomarkers market size is forecast to increase by USD 7.82 billion at a CAGR of 13.01% between 2023 and 2028. The market is experiencing significant growth due to the rising incidence of neurological disorders and the increasing focus on accurate neurological diagnostics. Neurological disorders, such as Alzheimer's disease, Parkinson's disease, and sleep disorders, pose a major health concern worldwide. Rapid and reliable diagnostic tools are essential to improve patient outcomes and reduce healthcare costs. One of the key trends in the market is the development of advanced technologies for the detection of biomarkers. Proteomic biomarkers, microarray technology, and digital biomarkers are gaining popularity due to their ability to provide accurate and early diagnosis. For instance, NeuraLight's digital biomarker platform uses machine learning to analyze sleep patterns and identify sleep disorders. Another trend is the use of non-invasive techniques for biomarker detection, such as rapid blood tests. These tests offer several advantages, including ease of use, quick turnaround time, and cost-effectiveness. Cardiac arrest and neurodegenerative diseases are some of the conditions that can be diagnosed using these tests. Despite the progress made in the field of neurological biomarkers, there are still unmet market needs for effective validation of biomarkers. Standardization of testing methods and regulatory approval are some of the challenges that need to be addressed to ensure the accuracy and reliability of biomarker tests. Addressing these challenges will help in the widespread adoption of neurological biomarkers and improve patient care.
To learn more about the neurological biomarkers market report, Request Free Sample
Neurological disorders, including Alzheimer's disease (AD), Parkinson's disease, dementia, brain tumors, epilepsy, virus neurological implications, stroke, autism, major depressive disorder, and other conditions, pose significant challenges to healthcare providers in terms of accurate diagnosis and effective treatment. The need for reliable biomarkers to aid in the early detection and monitoring of neurological disorders has gained considerable attention in recent years. Biomarkers are measurable indicators of biological processes or conditions in the body. In the context of neurological disorders, these markers can help physicians assess brain health, monitor disease progression, and evaluate treatment outcomes.
Blood-based biomarkers, in particular, have gained popularity due to their accessibility and ease of use. The application of biomarkers in neurology is not limited to the diagnosis of neurological disorders. They also play a crucial role in identifying lifestyle-related factors that contribute to the development and progression of these conditions. For instance, certain biomarkers, including cardiac biomarkers, can indicate inflammation, oxidative stress, or other factors that may increase the risk of neurological disorders. Despite the potential benefits of biomarkers, their implementation in clinical practice faces several challenges. One major challenge is the need for reliable and validated biomarkers. The use of unreliable biomarkers can lead to false diagnoses, incorrect treatment decisions, and adverse effects on patient privacy and data interpretation.
Another challenge is the delayed clinical trials associated with neurological disorders. The complex nature of these conditions and the difficulty in identifying reliable biomarkers have contributed to the slow pace of drug development and clinical trials. The integration of biomarkers into clinical trials can help accelerate the development of new treatments and therapies, including targeted therapies and precision medicine. The use of biomarkers in neurology also raises concerns regarding patient privacy and data interpretation. Ensuring the security and confidentiality of patient data is essential to maintaining trust and protecting patient privacy. Additionally, the interpretation of biomarker data requires specialized expertise and knowledge, highlighting the importance of healthcare providers' education and training in this area.
In conclusion, the neurological disorders biomarkers market holds significant potential for enhancing diagnostic tools and precision medicine. The development and implementation of reliable and validated biomarkers can lead to earlier and more accurate diagnoses, improved treatment outcomes, and a better understanding of the underlying causes of neurological disorders. Addressing the challenges associated with biomarker implementation, including the need for reliable biomarkers and data security, is crucial to realizing the full potential of this market.
The neurological biomarkers market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD billion" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.
The hospitals segment is estimated to witness significant growth during the forecast period.Neurological biomarkers play a significant role in diagnosing and monitoring neurological conditions, particularly in the geriatric population. Neurological disorders, including multiple sclerosis and neurodegenerative conditions, are increasingly prevalent due to the aging global population and lifestyle-related factors. Hospitals are the primary consumers of neurological biomarkers, with large hospitals, such as multispecialty hospitals and hospital groups, being the major contributors to market growth. These hospitals, which often have over 500 beds, accommodate a large number of patients with neurological disorders, leading to an increase in sales of neurological biomarker products. Medium-sized hospitals, with a limited number of supplier groups, rely on outsourced medical equipment and laboratory testing services to support their healthcare services.
The growing demand for diagnostic tools in precision medicine and targeted therapies for neurological conditions further boosts the market growth.
Get a glance at the market share of various segments. Request Free Sample
The Hospitals segment accounted for USD 2.18 billion in 2018 and showed a gradual increase during the forecast period.
North America is estimated to contribute 40% to the growth of the global neurological biomarkers market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
For more insights on the market share of various regions, Request Free Sample
Neurological biomarkers have gained significant attention due to their potential role in the clinical validation of neurological disorders, particularly in the context of personalized medicine. These biomarkers offer non-invasive and imaging-based diagnostic solutions, which are crucial for early detection and effective treatment of neurological conditions. For instance, Alzheimer's disease (AD), a leading neurological disorder in the US, affects approximately 6.2 million Americans aged 65 and above. With this number projected to reach 13.8 million by 2060, there is an urgent need for accurate and reliable diagnostic tools. In 2019, AD was the fifth-leading cause of death among Americans aged 65 and older, with 121,499 deaths recorded.
The high prevalence of neurological disorders, an aging population, escalating healthcare expenditure, and favorable reimbursement policies for neuro-diagnostic procedures are key factors fueling the growth of the market. The integration of advanced technologies such as artificial intelligence (AI) and machine learning (ML) in neurological diagnostics is also expected to boost market expansion during the forecast period. Neurological biomarkers hold immense promise in improving patient outcomes and reducing healthcare costs by enabling early and accurate diagnosis, personalized treatment plans, and effective disease management.
Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
Rising incidence of neurological disorders is the key driver of neurological biomarkers market growth. Neurological disorders, such as Alzheimer's disease, dementia, epilepsy, Parkinson's disease, and brain tumors, pose significant health risks to patients. These conditions can result in disabilities, including paralysis, and in some cases, can be fatal. Neurological disorders develop due to various causes, including bacterial and viral infections, genetic factors, and weakened immune responses. According to the Centers for Disease Control and Prevention (CDC), the prevalence of Parkinson's disease in the aging population (60-80 years) has risen from 1% to 4%. Neurological biomarkers play a crucial role in diagnosing and monitoring neurological disorders. For instance, Alzheimer's disease biomarkers, such as beta-amyloid and tau proteins, can help diagnose the condition in its early stages.
Similarly, Parkinson's disease biomarkers, such as dopamine levels and brain imaging, can aid in diagnosing and tracking disease progression. In summary, neurological biomarkers are essential tools for diagnosing and managing neurological disorders, including Alzheimer's disease, dementia, epilepsy, Parkinson's disease, and brain tumors.
Increasing focus on accurate neurological diagnostics is the upcoming trend in the neurological biomarkers market. Neurological disorders, including traumatic brain injuries (TBIs,) leave debilitating effects on individuals. While CT scans have been the go-to diagnostic tool for detecting brain injuries, their accuracy is often questionable, particularly in the case of mild TBIs. This limitation necessitates the exploration of alternative diagnostic methods. One such promising approach is the development of rapid blood tests for neurological biomarkers. Neurological biomarkers, such as sleep biomarkers and proteomic biomarkers, can provide more precise results for neurological disorders, including neurodegenerative diseases and cardiac arrest. companies are investing significantly in clinical trials and research and development (R&D) to bring these biomarkers to market.
Microarray technology and digital biomarkers are some of the advanced technologies being utilized in the detection of neurological biomarkers. These technologies offer the potential for earlier and more accurate diagnoses, enabling timely intervention and improved patient outcomes. As the demand for more precise neurological diagnostic tools continues to grow, the market for neurological biomarkers is expected to expand significantly. In conclusion, the inability of CT scans to accurately diagnose neurological disorders highlights the need for alternative diagnostic methods. Rapid blood tests for neurological biomarkers, such as sleep biomarkers and proteomic biomarkers, are gaining traction as they offer more precise results. Companies are investing in clinical trials and R&D to bring these biomarkers to market, utilizing advanced technologies like microarray technology and digital biomarkers to enhance their accuracy and accessibility.
Unmet market needs for effective validation of biomarkers is a key challenge affecting neurological biomarkers market growth. Neurological biomarkers have emerged as potential game-changers in the diagnosis and management of various neurological conditions, including stroke and major depressive disorder, among others. However, the slow adoption of these biomarkers can be attributed to several challenges. One of the primary hurdles is the lack of compelling evidence demonstrating the clinical and financial benefits of using these biomarkers. This is due to the difficulties in reproducing positive clinical trial results, the absence of rigorous pre-analytical examinations, and the need for independent validation of results. Moreover, the high cost of fluid-based proteomics, a promising approach for neurological disease biomarkers, hinders its widespread adoption.
To unlock the full potential of this technology, innovative strategies are required. For instance, autistic individuals and stroke patients can significantly benefit from early diagnosis and personalized treatment plans. However, physicians need reliable and cost-effective biomarkers to make informed decisions regarding their patients' brain health. Therefore, addressing these challenges and developing robust validation processes for neurological biomarkers is crucial to improving clinical practice and patient outcomes.
The neurological biomarkers market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the neurological biomarkers market growth analysis report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Abbott Laboratories - The company provides a portable blood analyzer, I STAT Alinity, for neurological biomarker detection. This user-friendly device delivers lab-quality diagnostic test results in real time. Neurological biomarkers play a crucial role in identifying neurological disorders, enabling early intervention and improved patient outcomes. I STAT Alinity simplifies the process of biomarker detection, providing accuracy and convenience for healthcare professionals. Neurological biomarkers, such as those detected by I STAT Alinity, are essential tools in the diagnosis and management of neurological conditions. This advanced technology contributes significantly to the neurological diagnostics market in the US, enhancing the overall efficiency and quality of patient care.
The neurological biomarkers market research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Neurological disorders, including Alzheimer's disease (AD), Parkinson's disease, dementia, brain tumors, epilepsy, and viral neurological implications, pose significant challenges for healthcare providers in diagnosing and treating patients. Biomarkers play a crucial role in advancing our understanding of these complex conditions and improving clinical outcomes. Blood-based biomarkers, such as proteomic markers identified through microarray technology, are gaining popularity due to their ease of use and reliability. AD and other neurodegenerative diseases, including major depressive disorder, autism, and multiple sclerosis, can be diagnosed using various biomarkers. These conditions affect a large geriatric population and are influenced by lifestyle-related factors. Rapid blood tests and sleep biomarkers are also being explored for their potential in diagnosing and monitoring these conditions.
Clinical diagnostics and drug development rely heavily on biomarkers for precision medicine and targeted therapies. Physicians use these tools to personalize treatment plans based on individual patient needs, improving treatment outcomes while minimizing adverse effects. Neuroimaging biomarkers and digital biomarkers, such as those offered by Neuralight, provide non-invasive alternatives for diagnosing and monitoring neurological conditions. Pharmaceutical firms are investing in clinical validations and clinical trials to develop new drugs and therapeutic research based on these biomarkers. As the aging global population continues to grow, the need for reliable biomarkers becomes increasingly important for patient privacy, data interpretation, sample preparation, and data analysis in clinical settings. Artificial intelligence and machine learning are also being integrated into biomarker research to enhance data analysis and improve diagnostic accuracy.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
175 |
|
Base year |
2023 |
|
Historic period |
2018-2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 13.01% |
|
Market growth 2024-2028 |
USD 7.82 billion |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
12.2 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 40% |
|
Key countries |
US, Germany, UK, France, and China |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
Abbott Laboratories, ACROBIOSYSTEMS INC., Advanced Brain Monitoring Inc., Alseres Pharmaceuticals Inc, Bio Rad Laboratories Inc., bioMerieux SA, Charles River Laboratories International Inc., EATRIS ERIC, Eli Lilly and Co., Enzo Biochem Inc., F. Hoffmann La Roche Ltd., Fujirebio Holdings Inc., IQVIA Holdings Inc., Merck KGaA, Metabolon Inc., PerkinElmer Inc, Proteome Sciences plc, QIAGEN NV, Quanterix Corp., and Thermo Fisher Scientific Inc. |
|
Market dynamics |
Parent market analysis, market growth inducers and obstacles, market forecast, fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, market condition analysis for the forecast period |
|
Customization purview |
If our neurological biomarkers market forecast report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this neurological biomarkers market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by End-user
7 Market Segmentation by Indication
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
